A new report says only using BMI to determine if a patient has obesity leads to under-diagnosing people who are ill and ...

The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss according to a University of Illinois professor ...

LONDON: Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...

But now that these drugs are in greater demand from both patients and doctors, state Medicaid programs are grappling with whether to cover them for weight loss, both for reasons of equity and to save ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

The just-published findings reveal what regulates a gene that’s pivotal to our food intake - and also our risk of obesity.

The FDA has designed five different types of labels, each presenting the same information but with different specifications based on the size of the packaging.